This page shows the latest Age-related macular degeneration news and features for those working in and with pharma, biotech and healthcare.
GA is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss.
AbbVie and REGENXBIO have formed a strategic partnership to develop and commercialise a potential gene therapy for wet age-related macular degeneration (AMD), diabetic retinopathy (DR) and other chronic retinal diseases. ... DR is the leading cause of
Byoovis is designed for the treatment of wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema, proliferative diabetic retinopathy, visual impairment due to macular oedema secondary to
Wet AMD is the leading cause of severe vision loss and legal blindness in people over the age of 65. ... Novartis and smartpatient have launched a new educational app experience for patients with age-related wet macular degeneration (AMD).
Beovu (brolucizumab) is the first anti-VEGF treatment to demonstrate superior resolution of retinal fluid compared to Eylea (aflibercept) in patients with wet age-related macular degeneration (AMD), according to Novartis.
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
More from news
Approximately 1 fully matching, plus 123 partially matching documents found.
for advanced dry Age-related Macular Degeneration (AMD). ... She became Britain’s youngest hospital leader when she was appointed chief executive of Birmingham Children’s Hospital in 2007 at the age of 32, subsequently helping it win Provider Trust
RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... A phase 2 study in the condition Geographic Atrophy (GA), which is the advanced stage of dry
treatments for age-related macular degeneration (AMD).
to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD). ... Despite the uncertainty and challenges in our environment, particularly related to Brexit, we need
company. Avalanche's preclinical and research stage gene therapy programmes are focused on a range of ophthalmic diseases, such as wet age-related macular degeneration, utilising adeno-associated virus (AAV) vectors. ... Onxeo is paying around $1.85m
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
She said: “I am excited to be joining Gyroscope at the company’s founding stage to advance new genetically-defined therapies for the treatment of debilitating eye diseases such as ... related macular degeneration.
While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of ... Because of my mother, I was on the other side
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...